Summary

The global ICSI Injection Micropipettes market is projected to grow from US$ 38.72 million in 2025 to US$ 55.96 million by 2032, at a CAGR of 5.4% (2026-2032), driven by critical product segments and diverse end‑use applications. ICSI Injection Micropipette is a specialized micromanipulation tool used in assisted reproductive laboratories for intracytoplasmic sperm injection. It is typically manufactured from fine glass capillary tubing with a sharp, beveled or spiked tip and is operated together with a micromanipulator and microinjection system. Its primary function is to aspirate and control a selected and immobilized single sperm under microscopic observation, penetrate the zona pellucida and oolemma of a stabilized oocyte, and release the sperm directly into the ooplasm to complete intracytoplasmic sperm injection. Product design focuses on tip configuration, lumen geometry, taper profile, bending angle, surface finish and manufacturing consistency to provide reliable sperm handling, controlled oocyte penetration and precise cytoplasmic injection while minimizing mechanical damage to the oocyte. ICSI micropipettes are specialized consumables for assisted reproductive micromanipulation and are functionally distinct from holding pipettes, which are used to stabilize the oocyte during the injection procedure. Key Findings ICSI accounts for around 73% of fertilization treatments worldwide and remains the dominant assisted fertilization technique Mainstream international channel prices are approximately US$18–20 per micropipette, commonly supplied in packs of ten Spiked designs and inner diameters below 6 μm form the core configuration of mainstream clinical ICSI micropipettes Fertility clinics and IVF centers constitute the primary downstream users, while hospital reproductive centers provide another major demand base Market Trends The ICSI Injection Micropipette market is evolving from basic glass injection tools toward highly standardized microtools optimized for reproducibility, lower oocyte trauma and embryologist-specific handling preferences. Major suppliers increasingly offer multiple combinations of spike design, lumen diameter, taper geometry, bend angle and tip-to-bend distance rather than a single universal specification. Long parallel-wall and slim designs are being developed to improve fluid control and reduce entry diameter, while rigid short-taper designs remain important for users seeking greater puncture stiffness. Large-bore models address surgically retrieved sperm, and flat-tip or dedicated Piezo injection pipettes are expanding the technical range of the market. Manufacturing is also becoming more controlled: CooperSurgical uses automated production and repeated dimensional inspection, while Kitazato and ASTEC emphasize individually inspected precision manufacturing and ICSION offers customized specifications. Cleanroom manufacture, individual sterile packaging, traceability, MEA and endotoxin testing are increasingly becoming core purchasing considerations rather than secondary features. Market Dynamics Drivers Demand is fundamentally supported by the large and recurring global ART treatment base and the high penetration of ICSI within assisted fertilization. ESHRE reports more than three million registered ART cycles annually worldwide and estimates actual activity at around four million cycles after allowing for incomplete registry coverage; ICSI accounts for about 73% of fertilization treatments. Male-factor infertility remains the core clinical foundation for ICSI, while previous poor or failed fertilization and selected use after oocyte cryopreservation provide additional procedure demand. Because ICSI requires direct sperm aspiration and oocyte injection through a precision microtool, each expansion in the number of ICSI-performing embryology laboratories generates recurring demand for sterile single-use injection micropipettes. Restraints The market is constrained by the already-high penetration of ICSI, slowing ART growth in some mature markets and the relatively low value of each disposable micropipette. ESHRE notes that ART cycle growth in many developed countries has historically been in the mid- to high-single-digit range but is showing signs of moderation, while CooperSurgical also reported periods of softer fertility activity during 2025. In addition, broader use of ICSI is not automatically supported for every non-male-factor IVF cycle; the 2026 ASRM committee opinion continues to distinguish clearly indicated ICSI from routine use in patients with normal semen parameters. These factors limit the extent to which growth can be generated simply by increasing ICSI penetration, making treatment volume, geographic expansion and supplier share gains more important. Opportunities The strongest opportunities lie in geographic expansion, localized manufacturing and increasingly differentiated microtool designs. Major suppliers are expanding distribution into North America, Europe and Asia, while Chinese manufacturers such as VitaVitro, DEWIN and Minvitro have established domestic ICSI injection or micromanipulation product lines, creating additional substitution opportunities in a market historically led by imported microtools. Product-level opportunities are emerging around lower-trauma slim designs, customized dimensions, large-bore pipettes for surgically retrieved sperm and Piezo-compatible injection pipettes. ICSION already supplies dedicated Piezo injection models and CooperSurgical offers flat-tip products for Piezo-ICSI, while DEWIN also includes Piezo tools within its micromanipulation portfolio. Customized production is particularly attractive because embryologists often maintain strong preferences for taper stiffness, fluid response, spike shape and bend geometry. Challenges ICSI micropipettes are structurally simple but demanding to manufacture consistently because minute variations in inner diameter, bevel, spike formation, taper length, bend angle or surface defects can materially change handling characteristics during microinjection. Suppliers must therefore combine precision glass processing with cleanroom control, dimensional inspection, sterilization and embryo-compatible biological testing. CooperSurgical performs full visual inspection throughout production and uses gamma sterilization together with MEA and LAL testing, while Labotect uses individually sterile packaging and validated electron-beam sterilization. Another challenge is that embryologist preference is highly operator-specific: flexible long-parallel tapers, rigid short tapers, spiked tips and non-spiked tips can all be preferred in different laboratories. This limits complete SKU standardization, increases high-mix manufacturing requirements and makes clinical familiarity, training, distributor support and reliable supply important competitive factors alongside price. Industry Chain Analysis The upstream chain is centered on high-purity borosilicate glass capillary tubing, polymer holders and protective packaging, precision forming and inspection equipment, cleanroom infrastructure and sterilization services. Midstream production involves capillary cleaning, heating and pulling, taper formation, lumen control, beveling and spike fabrication, bending, polishing, dimensional inspection, cleaning, sterile packaging and biological quality control. CooperSurgical explicitly identifies cleaning, heating and sonication of borosilicate capillaries as part of its process, while VITROMED manufactures injection pipettes from specially cleaned borosilicate glass under cleanroom conditions. Finished products reach users through global direct-sales organizations and specialist IVF distributors, with independent fertility clinics, IVF centers and hospital reproductive medicine laboratories forming the principal clinical customer base and academic or research laboratories representing a smaller specialized segment. The value added is concentrated less in raw glass cost than in precision processing, process reproducibility, quality assurance, regulatory compliance and dependable global distribution. Segment Insights By tip configuration, spiked ICSI micropipettes remain the mainstream architecture. CooperSurgical states that most of its ORIGIO ICSI micropipettes use fine spikes, while Vitrolife and Kitazato maintain extensive spiked product ranges; non-spiked products remain relevant for embryologists preferring a sharp bevel without an additional spike. By inner diameter, products below 5.0 μm and those from 5.0 to below 6.0 μm cover the core conventional ICSI range, reflecting the need to balance sperm aspiration, fluid control and a small oocyte entry point. Products at 6.0 μm and above form a more specialized segment, including designs intended to facilitate handling of surgically retrieved sperm or spermatids. By taper design, long parallel-wall products emphasize fine fluid control and flexibility, short parallel-wall products provide a different balance between control and stiffness, and rigid-taper designs serve embryologists who prefer greater tip rigidity during penetration. The continued coexistence of these designs indicates that operator preference and laboratory technique remain important determinants of product selection. Downstream Market Opportunities Independent fertility clinics and IVF centers account for the principal commercial demand because ICSI is performed routinely in dedicated embryology laboratories equipped with inverted microscopes, micromanipulators and injection systems. Hospital-based reproductive medicine centers constitute another important customer segment, particularly in markets where ART services are concentrated in university hospitals, maternity hospitals or large medical systems. Academic and research laboratories represent a much smaller but technically important market for micromanipulation research, embryology training and method development. Future downstream opportunities are increasingly associated with large IVF clinic groups seeking standardized consumables across multiple laboratories, expansion of ART capacity in emerging markets, increasing treatment of complex male-factor infertility and greater demand for product traceability and consistent handling performance. Specialized clinical scenarios such as surgically retrieved sperm and Piezo-ICSI also support higher product differentiation even though they remain smaller than conventional ICSI. Regional Insights Europe and North America remain major high-value markets for ICSI Injection Micropipettes because of their mature ART infrastructure, extensive clinic networks and established use of regulated single-use laboratory consumables. Europe represents an exceptionally large documented ART base, while the United States combines substantial procedure volume with relatively high consumable pricing. Asia-Pacific provides the largest long-term volume opportunity through major ART markets including China and Japan, although near-term treatment growth can vary significantly by country. ESHRE identifies China at around one million ART cycles annually and Japan as one of the world's most active officially reported ART markets, while Kitazato identifies the United States, Europe, China and other overseas markets as strategic areas for continued expansion. Regional competition is also becoming more localized: European and North American brands retain strong premium positions, while Chinese suppliers are broadening domestic ICSI microtool portfolios and international registrations. Competitive Landscape Analysis The competitive landscape combines diversified global ART platforms with highly specialized micropipette manufacturers and increasingly capable regional suppliers. CooperSurgical has one of the strongest manufacturing positions, producing more than 1.5 million ORIGIO micropipettes annually across ICSI and other micromanipulation applications, while Vitrolife and Kitazato combine ICSI microtools with broader IVF consumable portfolios. Nexpring Health has emerged as an important consolidated ART platform incorporating Cook Reproductive Health, Hamilton Thorne, Gynemed, Gynétics, IVFtech, Planer and Irvine Scientific. Sunlight Medical, VITROMED, ASTEC, Labotect, Microtech IVF, Synga, ICSION Medical, ARSCI and Optimas compete through specialist microtool know-how, customization and embryologist-oriented designs. Chinese producers including VitaVitro, DEWIN, WEGO Shingene Medical, Lingen Precision Medical Products and Minvitro are strengthening domestic supply and widening the competitive field. Competition therefore centers on dimensional consistency, tip design, biological safety testing, clinical familiarity, specification breadth, distributor reach and reliable supply rather than on price alone. Report Scope This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global ICSI Injection Micropipettes market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers. By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern. Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed. Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths. A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand. Market Segmentation By Company CooperSurgical Nexpring Health Vitrolife Kitazato Sunlight Medical VITROMED ASTEC Labotect Thomas Medical Microtech IVF Synga ARSCI Optimas ICSION Medical Monash Biotech Reproline medical TechBruein SASOmed VitaVitro DEWIN WEGO Shingene Medical Lingen Precision Medical Products Diagens Bio Minvitro Segment by Type Spiked Non-Spiked Segment by Inner Diameter <5.0 μm 5.0–<6.0 μm ≥6.0 μm Segment by Taper Design Long Parallel-Wall Short Parallel-Wall Rigid-Taper Segment by Application Fertility Clinics and IVF Centers Hospital-Based Reproductive Medicine Centers Academic and Research Laboratories Others Sales by Region North America U.S. Canada Mexico Asia-Pacific China Japan South Korea India China Taiwan Southeast Asia (Indonesia, Vietnam, Thailand) Europe Germany France U.K. Italy Russia Central and South America Brazil Argentina Rest of Central and South America Middle East, Africa Turkey Egypt GCC Countries South Africa Chapter Outline Chapter 1: Defines the ICSI Injection Micropipettes study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies Chapter 14: Actionable conclusions and strategic recommendations. Why This Report Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to: Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5). Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence. Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11). Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13). Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage 1.1 Introduction to ICSI Injection Micropipettes: Definition, Properties, and Key Attributes 1.2 Market Segmentation by Type 1.2.1 Global ICSI Injection Micropipettes Market Size by Type, 2021 vs 2025 vs 2032 1.2.2 Spiked 1.2.3 Non-Spiked 1.3 Market Segmentation by Inner Diameter 1.3.1 Global ICSI Injection Micropipettes Market Size by Inner Diameter, 2021 vs 2025 vs 2032 1.3.2 <5.0 μm 1.3.3 5.0–<6.0 μm 1.3.4 ≥6.0 μm 1.4 Market Segmentation by Taper Design 1.4.1 Global ICSI Injection Micropipettes Market Size by Taper Design, 2021 vs 2025 vs 2032 1.4.2 Long Parallel-Wall 1.4.3 Short Parallel-Wall 1.4.4 Rigid-Taper 1.5 Market Segmentation by Application 1.5.1 Global ICSI Injection Micropipettes Market Size by Application, 2021 vs 2025 vs 2032 1.5.2 Fertility Clinics and IVF Centers 1.5.3 Hospital-Based Reproductive Medicine Centers 1.5.4 Academic and Research Laboratories 1.5.5 Others 1.6 Assumptions and Limitations 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary 2.1 Global ICSI Injection Micropipettes Revenue Estimates and Forecasts (2021-2032) 2.2 Global ICSI Injection Micropipettes Revenue by Region 2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032 2.2.2 Historical and Forecasted Revenue by Region (2021-2032) 2.2.3 Global Revenue-Based Market Share by Region (2021-2032) 2.3 Global ICSI Injection Micropipettes Sales Estimates and Forecasts (2021-2032) 2.4 Global ICSI Injection Micropipettes Sales by Region 2.4.1 Sales Comparison: 2021 vs 2025 vs 2032 2.4.2 Historical and Forecasted Sales by Region (2021-2032) 2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends 2.4.4 Global Sales Market Share by Region (2021-2032) 3 Competitive Landscape 3.1 Global ICSI Injection Micropipettes Sales by Manufacturers 3.1.1 Global Sales Volume by Manufacturers (2021-2026) 3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025) 3.2 Global ICSI Injection Micropipettes Manufacturer Revenue Rankings and Tiers 3.2.1 Global Revenue (Value) by Manufacturers (2021-2026) 3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025) 3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3) 3.3 Manufacturer Profitability Profiles and Pricing Strategies 3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025) 3.3.2 Manufacturer-Level Price Trends (2021-2026) 3.4 Key Manufacturers Manufacturing Base and Headquarters 3.5 Key Manufacturers Market Share by Product Type 3.5.1 Spiked: Market Share by Key Manufacturers 3.5.2 Non-Spiked: Market Share by Key Manufacturers 3.6 Global ICSI Injection Micropipettes Market Concentration and Dynamics 3.6.1 Global Market Concentration 3.6.2 Entrant/Exit Impact Analysis 3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment 4 Product Segmentation 4.1 Global ICSI Injection Micropipettes Sales Performance by Type 4.1.1 Global ICSI Injection Micropipettes Sales Volume by Type (2021-2032) 4.1.2 Global ICSI Injection Micropipettes Revenue by Type (2021-2032) 4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032) 4.2 Global ICSI Injection Micropipettes Sales Performance by Inner Diameter 4.2.1 Global ICSI Injection Micropipettes Sales Volume by Inner Diameter (2021-2032) 4.2.2 Global ICSI Injection Micropipettes Revenue by Inner Diameter (2021-2032) 4.2.3 Global Average Selling Price (ASP) Trends by Inner Diameter (2021-2032) 4.3 Global ICSI Injection Micropipettes Sales Performance by Taper Design 4.3.1 Global ICSI Injection Micropipettes Sales Volume by Taper Design (2021-2032) 4.3.2 Global ICSI Injection Micropipettes Revenue by Taper Design (2021-2032) 4.3.3 Global Average Selling Price (ASP) Trends by Taper Design (2021-2032) 4.4 Product Technology Differentiation 4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk 4.5.1 High-Growth Niches and Adoption Drivers 4.5.2 Profitability Hotspots and Cost Drivers 4.5.3 Substitution Threats 5 Downstream Applications and Customers 5.1 Global ICSI Injection Micropipettes Sales by Application 5.1.1 Global Historical and Forecasted Sales by Application (2021-2032) 5.1.2 Global Sales Market Share by Application (2021-2032) 5.1.3 High-Growth Application Identification 5.1.4 Emerging Application Case Studies 5.2 Global ICSI Injection Micropipettes Revenue by Application 5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032) 5.2.2 Revenue-Based Market Share by Application (2021-2032) 5.3 Global Pricing Dynamics by Application (2021-2032) 5.4 Downstream Customer Analysis 5.4.1 Top Customers by Region 5.4.2 Top Customers by Application 6 North America 6.1 North America Sales Volume and Revenue (2021-2032) 6.2 North America Key Manufacturers Sales Revenue in 2025 6.3 North America ICSI Injection Micropipettes Sales and Revenue by Application (2021-2032) 6.4 North America Growth Accelerators and Market Barriers 6.5 North America ICSI Injection Micropipettes Market Size by Country 6.5.1 North America Revenue by Country 6.5.2 North America Sales Trends by Country 6.5.3 US 6.5.4 Canada 6.5.5 Mexico 7 Europe 7.1 Europe Sales Volume and Revenue (2021-2032) 7.2 Europe Key Manufacturers Sales Revenue in 2025 7.3 Europe ICSI Injection Micropipettes Sales and Revenue by Application (2021-2032) 7.4 Europe Growth Accelerators and Market Barriers 7.5 Europe ICSI Injection Micropipettes Market Size by Country 7.5.1 Europe Revenue by Country 7.5.2 Europe Sales Trends by Country 7.5.3 Germany 7.5.4 France 7.5.5 U.K. 7.5.6 Italy 7.5.7 Russia 8 Asia-Pacific 8.1 Asia-Pacific Sales Volume and Revenue (2021-2032) 8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025 8.3 Asia-Pacific ICSI Injection Micropipettes Sales and Revenue by Application (2021-2032) 8.4 Asia-Pacific ICSI Injection Micropipettes Market Size by Region 8.4.1 Asia-Pacific Revenue by Region 8.4.2 Asia-Pacific Sales Trends by Region 8.5 Asia-Pacific Growth Accelerators and Market Barriers 8.6 Southeast Asia 8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032) 8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines 8.7 China 8.8 Japan 8.9 South Korea 8.10 China Taiwan 8.11 India 9 Central and South America 9.1 Central and South America Sales Volume and Revenue (2021-2032) 9.2 Central and South America Key Manufacturers Sales Revenue in 2025 9.3 Central and South America ICSI Injection Micropipettes Sales and Revenue by Application (2021-2032) 9.4 Central and South America Investment Opportunities and Key Challenges 9.5 Central and South America ICSI Injection Micropipettes Market Size by Country 9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032) 9.5.2 Brazil 9.5.3 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Sales Volume and Revenue (2021-2032) 10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025 10.3 Middle East and Africa ICSI Injection Micropipettes Sales and Revenue by Application (2021-2032) 10.4 Middle East and Africa Investment Opportunities and Key Challenges 10.5 Middle East and Africa ICSI Injection Micropipettes Market Size by Country 10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032) 10.5.2 GCC Countries 10.5.3 Turkey 10.5.4 Egypt 10.5.5 South Africa 11 Corporate Profile 11.1 CooperSurgical 11.1.1 CooperSurgical Corporation Information 11.1.2 CooperSurgical Business Overview 11.1.3 CooperSurgical ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.1.4 CooperSurgical ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.1.5 CooperSurgical ICSI Injection Micropipettes Sales by Product in 2025 11.1.6 CooperSurgical ICSI Injection Micropipettes Sales by Application in 2025 11.1.7 CooperSurgical ICSI Injection Micropipettes Sales by Geographic Area in 2025 11.1.8 CooperSurgical ICSI Injection Micropipettes SWOT Analysis 11.1.9 CooperSurgical Recent Developments 11.2 Nexpring Health 11.2.1 Nexpring Health Corporation Information 11.2.2 Nexpring Health Business Overview 11.2.3 Nexpring Health ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.2.4 Nexpring Health ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.2.5 Nexpring Health ICSI Injection Micropipettes Sales by Product in 2025 11.2.6 Nexpring Health ICSI Injection Micropipettes Sales by Application in 2025 11.2.7 Nexpring Health ICSI Injection Micropipettes Sales by Geographic Area in 2025 11.2.8 Nexpring Health ICSI Injection Micropipettes SWOT Analysis 11.2.9 Nexpring Health Recent Developments 11.3 Vitrolife 11.3.1 Vitrolife Corporation Information 11.3.2 Vitrolife Business Overview 11.3.3 Vitrolife ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.3.4 Vitrolife ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.3.5 Vitrolife ICSI Injection Micropipettes Sales by Product in 2025 11.3.6 Vitrolife ICSI Injection Micropipettes Sales by Application in 2025 11.3.7 Vitrolife ICSI Injection Micropipettes Sales by Geographic Area in 2025 11.3.8 Vitrolife ICSI Injection Micropipettes SWOT Analysis 11.3.9 Vitrolife Recent Developments 11.4 Kitazato 11.4.1 Kitazato Corporation Information 11.4.2 Kitazato Business Overview 11.4.3 Kitazato ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.4.4 Kitazato ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.4.5 Kitazato ICSI Injection Micropipettes Sales by Product in 2025 11.4.6 Kitazato ICSI Injection Micropipettes Sales by Application in 2025 11.4.7 Kitazato ICSI Injection Micropipettes Sales by Geographic Area in 2025 11.4.8 Kitazato ICSI Injection Micropipettes SWOT Analysis 11.4.9 Kitazato Recent Developments 11.5 Sunlight Medical 11.5.1 Sunlight Medical Corporation Information 11.5.2 Sunlight Medical Business Overview 11.5.3 Sunlight Medical ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.5.4 Sunlight Medical ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.5.5 Sunlight Medical ICSI Injection Micropipettes Sales by Product in 2025 11.5.6 Sunlight Medical ICSI Injection Micropipettes Sales by Application in 2025 11.5.7 Sunlight Medical ICSI Injection Micropipettes Sales by Geographic Area in 2025 11.5.8 Sunlight Medical ICSI Injection Micropipettes SWOT Analysis 11.5.9 Sunlight Medical Recent Developments 11.6 VITROMED 11.6.1 VITROMED Corporation Information 11.6.2 VITROMED Business Overview 11.6.3 VITROMED ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.6.4 VITROMED ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.6.5 VITROMED Recent Developments 11.7 ASTEC 11.7.1 ASTEC Corporation Information 11.7.2 ASTEC Business Overview 11.7.3 ASTEC ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.7.4 ASTEC ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.7.5 ASTEC Recent Developments 11.8 Labotect 11.8.1 Labotect Corporation Information 11.8.2 Labotect Business Overview 11.8.3 Labotect ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.8.4 Labotect ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.8.5 Labotect Recent Developments 11.9 Thomas Medical 11.9.1 Thomas Medical Corporation Information 11.9.2 Thomas Medical Business Overview 11.9.3 Thomas Medical ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.9.4 Thomas Medical ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.9.5 Thomas Medical Recent Developments 11.10 Microtech IVF 11.10.1 Microtech IVF Corporation Information 11.10.2 Microtech IVF Business Overview 11.10.3 Microtech IVF ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.10.4 Microtech IVF ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.10.5 Microtech IVF Recent Developments 11.11 Synga 11.11.1 Synga Corporation Information 11.11.2 Synga Business Overview 11.11.3 Synga ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.11.4 Synga ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.11.5 Synga Recent Developments 11.12 ARSCI 11.12.1 ARSCI Corporation Information 11.12.2 ARSCI Business Overview 11.12.3 ARSCI ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.12.4 ARSCI ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.12.5 ARSCI Recent Developments 11.13 Optimas 11.13.1 Optimas Corporation Information 11.13.2 Optimas Business Overview 11.13.3 Optimas ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.13.4 Optimas ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.13.5 Optimas Recent Developments 11.14 ICSION Medical 11.14.1 ICSION Medical Corporation Information 11.14.2 ICSION Medical Business Overview 11.14.3 ICSION Medical ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.14.4 ICSION Medical ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.14.5 ICSION Medical Recent Developments 11.15 Monash Biotech 11.15.1 Monash Biotech Corporation Information 11.15.2 Monash Biotech Business Overview 11.15.3 Monash Biotech ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.15.4 Monash Biotech ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.15.5 Monash Biotech Recent Developments 11.16 Reproline medical 11.16.1 Reproline medical Corporation Information 11.16.2 Reproline medical Business Overview 11.16.3 Reproline medical ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.16.4 Reproline medical ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.16.5 Reproline medical Recent Developments 11.17 TechBruein 11.17.1 TechBruein Corporation Information 11.17.2 TechBruein Business Overview 11.17.3 TechBruein ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.17.4 TechBruein ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.17.5 TechBruein Recent Developments 11.18 SASOmed 11.18.1 SASOmed Corporation Information 11.18.2 SASOmed Business Overview 11.18.3 SASOmed ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.18.4 SASOmed ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.18.5 SASOmed Recent Developments 11.19 VitaVitro 11.19.1 VitaVitro Corporation Information 11.19.2 VitaVitro Business Overview 11.19.3 VitaVitro ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.19.4 VitaVitro ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.19.5 VitaVitro Recent Developments 11.20 DEWIN 11.20.1 DEWIN Corporation Information 11.20.2 DEWIN Business Overview 11.20.3 DEWIN ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.20.4 DEWIN ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.20.5 DEWIN Recent Developments 11.21 WEGO Shingene Medical 11.21.1 WEGO Shingene Medical Corporation Information 11.21.2 WEGO Shingene Medical Business Overview 11.21.3 WEGO Shingene Medical ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.21.4 WEGO Shingene Medical ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.21.5 WEGO Shingene Medical Recent Developments 11.22 Lingen Precision Medical Products 11.22.1 Lingen Precision Medical Products Corporation Information 11.22.2 Lingen Precision Medical Products Business Overview 11.22.3 Lingen Precision Medical Products ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.22.4 Lingen Precision Medical Products ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.22.5 Lingen Precision Medical Products Recent Developments 11.23 Diagens Bio 11.23.1 Diagens Bio Corporation Information 11.23.2 Diagens Bio Business Overview 11.23.3 Diagens Bio ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.23.4 Diagens Bio ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.23.5 Diagens Bio Recent Developments 11.24 Minvitro 11.24.1 Minvitro Corporation Information 11.24.2 Minvitro Business Overview 11.24.3 Minvitro ICSI Injection Micropipettes Product Models, Descriptions and Specifications 11.24.4 Minvitro ICSI Injection Micropipettes Sales, Price, Revenue and Gross Margin (2021-2026) 11.24.5 Minvitro Recent Developments 12 Value Chain and Supply-Chain Analysis 12.1 ICSI Injection Micropipettes Industry Chain 12.2 ICSI Injection Micropipettes Upstream Materials Analysis 12.2.1 Raw Materials 12.2.2 Key Suppliers Market Share & Risk Assessment 12.3 ICSI Injection Micropipettes Integrated Production Analysis 12.3.1 Manufacturing Footprint Analysis 12.3.2 Regional Production Market Share (2021-2032) 12.3.3 Regulatory and Trade Policy Impact on Production 12.3.4 Production Technology Overview 12.3.5 Regional Cost Drivers 12.4 ICSI Injection Micropipettes Sales Channels and Distribution Networks 12.4.1 Sales Channels 12.4.2 Distributors 13 ICSI Injection Micropipettes Market Dynamics 13.1 Industry Trends and Evolution 13.2 Market Growth Drivers and Emerging Opportunities 13.3 Market Challenges, Risks, and Restraints 13.4 Impact of U.S. Tariffs 14 Key Findings in the Global ICSI Injection Micropipettes Study 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.1.1 Research Programs/Design 15.1.1.2 Market Size Estimation 15.1.1.3 Market Breakdown and Data Triangulation 15.1.2 Data Source 15.1.2.1 Secondary Sources 15.1.2.2 Primary Sources 15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables Table 1. Global ICSI Injection Micropipettes Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Table 2. Global ICSI Injection Micropipettes Market Size Growth Rate by Inner Diameter, 2021 vs 2025 vs 2032 (US$ Million) Table 3. Global ICSI Injection Micropipettes Market Size Growth Rate by Taper Design, 2021 vs 2025 vs 2032 (US$ Million) Table 4. Global ICSI Injection Micropipettes Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Table 5. Global ICSI Injection Micropipettes Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 6. Global ICSI Injection Micropipettes Revenue by Region (US$ Million), 2021-2026 Table 7. Global ICSI Injection Micropipettes Revenue by Region (US$ Million), 2027-2032 Table 8. Global ICSI Injection Micropipettes Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units) Table 9. Global ICSI Injection Micropipettes Sales by Region (K Units), 2021-2026 Table 10. Global ICSI Injection Micropipettes Sales by Region (K Units), 2027-2032 Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 12. Global ICSI Injection Micropipettes Sales by Manufacturers (K Units), 2021-2026 Table 13. Global ICSI Injection Micropipettes Sales Share by Manufacturers (2021-2026) Table 14. Global ICSI Injection Micropipettes Revenue by Manufacturers (US$ Million), 2021-2026 Table 15. Global ICSI Injection Micropipettes Revenue-Based Market Share by Manufacturers (2021-2026) Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue) Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on ICSI Injection Micropipettes Revenue, 2025 Table 18. Global ICSI Injection Micropipettes Average Gross Margin (%) by Manufacturer (2021 vs 2025) Table 19. Global ICSI Injection Micropipettes Average Selling Price (ASP) by Manufacturers (US$/Unit), 2021-2026 Table 20. Key Manufacturers ICSI Injection Micropipettes Manufacturing Base and Headquarters Table 21. Global ICSI Injection Micropipettes Market Concentration Ratio (CR5) Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment Table 24. Global ICSI Injection Micropipettes Sales Volume by Type (K Units), 2021-2026 Table 25. Global ICSI Injection Micropipettes Sales Volume by Type (K Units), 2027-2032 Table 26. Global ICSI Injection Micropipettes Revenue by Type (US$ Million), 2021-2026 Table 27. Global ICSI Injection Micropipettes Revenue by Type (US$ Million), 2027-2032 Table 28. Global ICSI Injection Micropipettes Sales Volume by Inner Diameter (K Units), 2021-2026 Table 29. Global ICSI Injection Micropipettes Sales Volume by Inner Diameter (K Units), 2027-2032 Table 30. Global ICSI Injection Micropipettes Revenue by Inner Diameter (US$ Million), 2021-2026 Table 31. Global ICSI Injection Micropipettes Revenue by Inner Diameter (US$ Million), 2027-2032 Table 32. Global ICSI Injection Micropipettes Sales Volume by Taper Design (K Units), 2021-2026 Table 33. Global ICSI Injection Micropipettes Sales Volume by Taper Design (K Units), 2027-2032 Table 34. Global ICSI Injection Micropipettes Revenue by Taper Design (US$ Million), 2021-2026 Table 35. Global ICSI Injection Micropipettes Revenue by Taper Design (US$ Million), 2027-2032 Table 36. Technical Specifications by Key Product Type Table 37. Global ICSI Injection Micropipettes Sales by Application (K Units), 2021-2026 Table 38. Global ICSI Injection Micropipettes Sales by Application (K Units), 2027-2032 Table 39. ICSI Injection Micropipettes High-Growth Sectors Demand CAGR (2026-2032) Table 40. Global ICSI Injection Micropipettes Revenue by Application (US$ Million), 2021-2026 Table 41. Global ICSI Injection Micropipettes Revenue by Application (US$ Million), 2027-2032 Table 42. Top Customers by Region Table 43. Top Customers by Application Table 44. North America ICSI Injection Micropipettes Growth Accelerators and Market Barriers Table 45. North America ICSI Injection Micropipettes Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 46. North America ICSI Injection Micropipettes Sales (K Units) by Country (2021 vs 2025 vs 2032) Table 47. Europe ICSI Injection Micropipettes Growth Accelerators and Market Barriers Table 48. Europe ICSI Injection Micropipettes Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million) Table 49. Europe ICSI Injection Micropipettes Sales (K Units) by Country (2021 vs 2025 vs 2032) Table 50. Asia-Pacific ICSI Injection Micropipettes Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 51. Asia-Pacific ICSI Injection Micropipettes Sales (K Units) by Country (2021 vs 2025 vs 2032) Table 52. Asia-Pacific ICSI Injection Micropipettes Growth Accelerators and Market Barriers Table 53. Southeast Asia ICSI Injection Micropipettes Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 54. Central and South America ICSI Injection Micropipettes Investment Opportunities and Key Challenges Table 55. Central and South America ICSI Injection Micropipettes Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 56. Middle East and Africa ICSI Injection Micropipettes Investment Opportunities and Key Challenges Table 57. Middle East and Africa ICSI Injection Micropipettes Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 58. CooperSurgical Corporation Information Table 59. CooperSurgical Description and Major Businesses Table 60. CooperSurgical Product Models, Descriptions and Specifications Table 61. CooperSurgical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. CooperSurgical Sales Value Proportion by Product in 2025 Table 63. CooperSurgical Sales Value Proportion by Application in 2025 Table 64. CooperSurgical Sales Value Proportion by Geographic Area in 2025 Table 65. CooperSurgical ICSI Injection Micropipettes SWOT Analysis Table 66. CooperSurgical Recent Developments Table 67. Nexpring Health Corporation Information Table 68. Nexpring Health Description and Major Businesses Table 69. Nexpring Health Product Models, Descriptions and Specifications Table 70. Nexpring Health Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Nexpring Health Sales Value Proportion by Product in 2025 Table 72. Nexpring Health Sales Value Proportion by Application in 2025 Table 73. Nexpring Health Sales Value Proportion by Geographic Area in 2025 Table 74. Nexpring Health ICSI Injection Micropipettes SWOT Analysis Table 75. Nexpring Health Recent Developments Table 76. Vitrolife Corporation Information Table 77. Vitrolife Description and Major Businesses Table 78. Vitrolife Product Models, Descriptions and Specifications Table 79. Vitrolife Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Vitrolife Sales Value Proportion by Product in 2025 Table 81. Vitrolife Sales Value Proportion by Application in 2025 Table 82. Vitrolife Sales Value Proportion by Geographic Area in 2025 Table 83. Vitrolife ICSI Injection Micropipettes SWOT Analysis Table 84. Vitrolife Recent Developments Table 85. Kitazato Corporation Information Table 86. Kitazato Description and Major Businesses Table 87. Kitazato Product Models, Descriptions and Specifications Table 88. Kitazato Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Kitazato Sales Value Proportion by Product in 2025 Table 90. Kitazato Sales Value Proportion by Application in 2025 Table 91. Kitazato Sales Value Proportion by Geographic Area in 2025 Table 92. Kitazato ICSI Injection Micropipettes SWOT Analysis Table 93. Kitazato Recent Developments Table 94. Sunlight Medical Corporation Information Table 95. Sunlight Medical Description and Major Businesses Table 96. Sunlight Medical Product Models, Descriptions and Specifications Table 97. Sunlight Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Sunlight Medical Sales Value Proportion by Product in 2025 Table 99. Sunlight Medical Sales Value Proportion by Application in 2025 Table 100. Sunlight Medical Sales Value Proportion by Geographic Area in 2025 Table 101. Sunlight Medical ICSI Injection Micropipettes SWOT Analysis Table 102. Sunlight Medical Recent Developments Table 103. VITROMED Corporation Information Table 104. VITROMED Description and Major Businesses Table 105. VITROMED Product Models, Descriptions and Specifications Table 106. VITROMED Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. VITROMED Recent Developments Table 108. ASTEC Corporation Information Table 109. ASTEC Description and Major Businesses Table 110. ASTEC Product Models, Descriptions and Specifications Table 111. ASTEC Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. ASTEC Recent Developments Table 113. Labotect Corporation Information Table 114. Labotect Description and Major Businesses Table 115. Labotect Product Models, Descriptions and Specifications Table 116. Labotect Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Labotect Recent Developments Table 118. Thomas Medical Corporation Information Table 119. Thomas Medical Description and Major Businesses Table 120. Thomas Medical Product Models, Descriptions and Specifications Table 121. Thomas Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Thomas Medical Recent Developments Table 123. Microtech IVF Corporation Information Table 124. Microtech IVF Description and Major Businesses Table 125. Microtech IVF Product Models, Descriptions and Specifications Table 126. Microtech IVF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Microtech IVF Recent Developments Table 128. Synga Corporation Information Table 129. Synga Description and Major Businesses Table 130. Synga Product Models, Descriptions and Specifications Table 131. Synga Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Synga Recent Developments Table 133. ARSCI Corporation Information Table 134. ARSCI Description and Major Businesses Table 135. ARSCI Product Models, Descriptions and Specifications Table 136. ARSCI Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. ARSCI Recent Developments Table 138. Optimas Corporation Information Table 139. Optimas Description and Major Businesses Table 140. Optimas Product Models, Descriptions and Specifications Table 141. Optimas Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Optimas Recent Developments Table 143. ICSION Medical Corporation Information Table 144. ICSION Medical Description and Major Businesses Table 145. ICSION Medical Product Models, Descriptions and Specifications Table 146. ICSION Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. ICSION Medical Recent Developments Table 148. Monash Biotech Corporation Information Table 149. Monash Biotech Description and Major Businesses Table 150. Monash Biotech Product Models, Descriptions and Specifications Table 151. Monash Biotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Monash Biotech Recent Developments Table 153. Reproline medical Corporation Information Table 154. Reproline medical Description and Major Businesses Table 155. Reproline medical Product Models, Descriptions and Specifications Table 156. Reproline medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Reproline medical Recent Developments Table 158. TechBruein Corporation Information Table 159. TechBruein Description and Major Businesses Table 160. TechBruein Product Models, Descriptions and Specifications Table 161. TechBruein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. TechBruein Recent Developments Table 163. SASOmed Corporation Information Table 164. SASOmed Description and Major Businesses Table 165. SASOmed Product Models, Descriptions and Specifications Table 166. SASOmed Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. SASOmed Recent Developments Table 168. VitaVitro Corporation Information Table 169. VitaVitro Description and Major Businesses Table 170. VitaVitro Product Models, Descriptions and Specifications Table 171. VitaVitro Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. VitaVitro Recent Developments Table 173. DEWIN Corporation Information Table 174. DEWIN Description and Major Businesses Table 175. DEWIN Product Models, Descriptions and Specifications Table 176. DEWIN Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 177. DEWIN Recent Developments Table 178. WEGO Shingene Medical Corporation Information Table 179. WEGO Shingene Medical Description and Major Businesses Table 180. WEGO Shingene Medical Product Models, Descriptions and Specifications Table 181. WEGO Shingene Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 182. WEGO Shingene Medical Recent Developments Table 183. Lingen Precision Medical Products Corporation Information Table 184. Lingen Precision Medical Products Description and Major Businesses Table 185. Lingen Precision Medical Products Product Models, Descriptions and Specifications Table 186. Lingen Precision Medical Products Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 187. Lingen Precision Medical Products Recent Developments Table 188. Diagens Bio Corporation Information Table 189. Diagens Bio Description and Major Businesses Table 190. Diagens Bio Product Models, Descriptions and Specifications Table 191. Diagens Bio Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 192. Diagens Bio Recent Developments Table 193. Minvitro Corporation Information Table 194. Minvitro Description and Major Businesses Table 195. Minvitro Product Models, Descriptions and Specifications Table 196. Minvitro Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 197. Minvitro Recent Developments Table 198. Key Raw Materials Distribution Table 199. Raw Materials Key Suppliers Table 200. Critical Raw Material Supplier Concentration (2025) & Risk Index Table 201. Milestones in Production Technology Evolution Table 202. Distributors List Table 203. Market Trends and Market Evolution Table 204. Market Drivers and Opportunities Table 205. Market Challenges, Risks, and Restraints Table 206. Research Programs/Design for This Report Table 207. Key Data Information from Secondary Sources Table 208. Key Data Information from Primary Sources List of Figures Figure 1. ICSI Injection Micropipettes Product Picture Figure 2. Global ICSI Injection Micropipettes Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Figure 3. Spiked Product Picture Figure 4. Non-Spiked Product Picture Figure 5. Global ICSI Injection Micropipettes Market Size Growth Rate by Inner Diameter, 2021 vs 2025 vs 2032 (US$ Million) Figure 6. <5.0 μm Product Picture Figure 7. 5.0–<6.0 μm Product Picture Figure 8. ≥6.0 μm Product Picture Figure 9. Global ICSI Injection Micropipettes Market Size Growth Rate by Taper Design, 2021 vs 2025 vs 2032 (US$ Million) Figure 10. Long Parallel-Wall Product Picture Figure 11. Short Parallel-Wall Product Picture Figure 12. Rigid-Taper Product Picture Figure 13. Global ICSI Injection Micropipettes Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Figure 14. Fertility Clinics and IVF Centers Figure 15. Hospital-Based Reproductive Medicine Centers Figure 16. Academic and Research Laboratories Figure 17. Others Figure 18. ICSI Injection Micropipettes Report Years Considered Figure 19. Global ICSI Injection Micropipettes Revenue, (US$ Million), 2021 vs 2025 vs 2032 Figure 20. Global ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 21. Global ICSI Injection Micropipettes Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Figure 22. Global ICSI Injection Micropipettes Revenue-Based Market Share by Region (2021-2032) Figure 23. Global ICSI Injection Micropipettes Sales (K Units), 2021-2032 Figure 24. Global ICSI Injection Micropipettes Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units) Figure 25. Global ICSI Injection Micropipettes Sales Market Share by Region (2021-2032) Figure 26. Top 5 and Top 10 Manufacturers ICSI Injection Micropipettes Sales Volume Market Share in 2025 Figure 27. Global ICSI Injection Micropipettes Revenue-Based Market Share Ranking (2025) Figure 28. Tier Distribution by Revenue Contribution (2021 vs 2025) Figure 29. Spiked Revenue-Based Market Share by Manufacturer in 2025 Figure 30. Non-Spiked Revenue-Based Market Share by Manufacturer in 2025 Figure 31. Global ICSI Injection Micropipettes Sales Volume-Based Market Share by Type (2021-2032) Figure 32. Global ICSI Injection Micropipettes Revenue-Based Market Share by Type (2021-2032) Figure 33. Global ICSI Injection Micropipettes ASP by Type (US$/Unit), 2021-2032 Figure 34. Global ICSI Injection Micropipettes Sales Volume-Based Market Share by Inner Diameter (2021-2032) Figure 35. Global ICSI Injection Micropipettes Revenue-Based Market Share by Inner Diameter (2021-2032) Figure 36. Global ICSI Injection Micropipettes ASP by Inner Diameter (US$/Unit), 2021-2032 Figure 37. Global ICSI Injection Micropipettes Sales Volume-Based Market Share by Taper Design (2021-2032) Figure 38. Global ICSI Injection Micropipettes Revenue-Based Market Share by Taper Design (2021-2032) Figure 39. Global ICSI Injection Micropipettes ASP by Taper Design (US$/Unit), 2021-2032 Figure 40. Global ICSI Injection Micropipettes Sales Market Share by Application (2021-2032) Figure 41. Global ICSI Injection Micropipettes Revenue-Based Market Share by Application (2021-2032) Figure 42. Global ICSI Injection Micropipettes ASP by Application (US$/Unit), 2021-2032 Figure 43. North America ICSI Injection Micropipettes Sales YoY (K Units), 2021-2032 Figure 44. North America ICSI Injection Micropipettes Revenue YoY (US$ Million), 2021-2032 Figure 45. North America Top 5 Manufacturers ICSI Injection Micropipettes Sales Revenue (US$ Million) in 2025 Figure 46. North America ICSI Injection Micropipettes Sales Volume (K Units) by Application (2021-2032) Figure 47. North America ICSI Injection Micropipettes Sales Revenue (US$ Million) by Application (2021-2032) Figure 48. US ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 49. Canada ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 50. Mexico ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 51. Europe ICSI Injection Micropipettes Sales YoY (K Units), 2021-2032 Figure 52. Europe ICSI Injection Micropipettes Revenue YoY (US$ Million), 2021-2032 Figure 53. Europe Top 5 Manufacturers ICSI Injection Micropipettes Sales Revenue (US$ Million) in 2025 Figure 54. Europe ICSI Injection Micropipettes Sales Volume (K Units) by Application (2021-2032) Figure 55. Europe ICSI Injection Micropipettes Sales Revenue (US$ Million) by Application (2021-2032) Figure 56. Germany ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 57. France ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 58. U.K. ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 59. Italy ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 60. Russia ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 61. Asia-Pacific ICSI Injection Micropipettes Sales YoY (K Units), 2021-2032 Figure 62. Asia-Pacific ICSI Injection Micropipettes Revenue YoY (US$ Million), 2021-2032 Figure 63. Asia-Pacific Top 8 Manufacturers ICSI Injection Micropipettes Sales Revenue (US$ Million) in 2025 Figure 64. Asia-Pacific ICSI Injection Micropipettes Sales Volume (K Units) by Application (2021-2032) Figure 65. Asia-Pacific ICSI Injection Micropipettes Sales Revenue (US$ Million) by Application (2021-2032) Figure 66. Indonesia ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 67. Japan ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 68. South Korea ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 69. China Taiwan ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 70. India ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 71. Central and South America ICSI Injection Micropipettes Sales YoY (K Units), 2021-2032 Figure 72. Central and South America ICSI Injection Micropipettes Revenue YoY (US$ Million), 2021-2032 Figure 73. Central and South America Top 5 Manufacturers ICSI Injection Micropipettes Sales Revenue (US$ Million) in 2025 Figure 74. Central and South America ICSI Injection Micropipettes Sales Volume (K Units) by Application (2021-2032) Figure 75. Central and South America ICSI Injection Micropipettes Sales Revenue (US$ Million) by Application (2021-2032) Figure 76. Brazil ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 77. Argentina ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 78. Middle East, and Africa ICSI Injection Micropipettes Sales YoY (K Units), 2021-2032 Figure 79. Middle East and Africa ICSI Injection Micropipettes Revenue YoY (US$ Million), 2021-2032 Figure 80. Middle East and Africa Top 5 Manufacturers ICSI Injection Micropipettes Sales Revenue (US$ Million) in 2025 Figure 81. Middle East and Africa ICSI Injection Micropipettes Sales Volume (K Units) by Application (2021-2032) Figure 82. Middle East and Africa ICSI Injection Micropipettes Sales Revenue (US$ Million) by Application (2021-2032) Figure 83. GCC Countries ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 84. Turkey ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 85. Egypt ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 86. South Africa ICSI Injection Micropipettes Revenue (US$ Million), 2021-2032 Figure 87. ICSI Injection Micropipettes Industry Chain Mapping Figure 88. Regional ICSI Injection Micropipettes Manufacturing Base Distribution (%) Figure 89. Global ICSI Injection Micropipettes Production Market Share by Region (2021-2032) Figure 90. ICSI Injection Micropipettes Production Process Figure 91. Regional ICSI Injection Micropipettes Production Cost Structure Figure 92. Channels of Distribution (Direct Vs Distribution) Figure 93. Bottom-up and Top-down Approaches for This Report Figure 94. Data Triangulation Figure 95. Key Executives Interviewed